BR112015017397A2 - compostos pirimidona bicíclica como inibidores de lp-pla2 - Google Patents
compostos pirimidona bicíclica como inibidores de lp-pla2Info
- Publication number
- BR112015017397A2 BR112015017397A2 BR112015017397A BR112015017397A BR112015017397A2 BR 112015017397 A2 BR112015017397 A2 BR 112015017397A2 BR 112015017397 A BR112015017397 A BR 112015017397A BR 112015017397 A BR112015017397 A BR 112015017397A BR 112015017397 A2 BR112015017397 A2 BR 112015017397A2
- Authority
- BR
- Brazil
- Prior art keywords
- pla2 inhibitors
- pyrimidone compounds
- compounds
- pla2
- bicyclic pyrimidone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Abstract
resumo “compostos pirimidona bicíclica como inibidores de lp-pla2 “ a presente invenção relaciona-se a novos compostos pirimido[1,6-a]pirimidin-6(2h)-ona que inibem a atividade lp-pla2, processos para sua prepara-ção, composições contendo os mesmos e seus usos no tratamento de doenças as-sociadas com a atividade da lp-pla2, como por exemplo, aterosclerose, doença de alzheimer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2013070977 | 2013-01-25 | ||
PCT/CN2014/071206 WO2014114249A1 (en) | 2013-01-25 | 2014-01-23 | Bicyclic pyrimidone compounds as inhibitors of lp-pla2 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015017397A2 true BR112015017397A2 (pt) | 2017-07-11 |
Family
ID=51226939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015017397A BR112015017397A2 (pt) | 2013-01-25 | 2014-01-23 | compostos pirimidona bicíclica como inibidores de lp-pla2 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20150344485A1 (pt) |
EP (1) | EP2948456A4 (pt) |
JP (1) | JP2016505053A (pt) |
KR (1) | KR20150108896A (pt) |
AU (1) | AU2014210260B2 (pt) |
BR (1) | BR112015017397A2 (pt) |
CA (1) | CA2899143A1 (pt) |
RU (1) | RU2015135824A (pt) |
WO (1) | WO2014114249A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6625603B2 (ja) | 2014-07-22 | 2019-12-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
CN105777653A (zh) * | 2014-12-26 | 2016-07-20 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的嘧啶酮类化合物及其药物组合物 |
CN106188063A (zh) * | 2015-05-08 | 2016-12-07 | 中国科学院上海药物研究所 | 用作Lp-PLA2抑制剂的双环类化合物、其制备方法及医药用途 |
CN105001098B (zh) * | 2015-07-26 | 2016-09-14 | 嵊州市油脂化工有限公司 | 一种3(r)/(s)-氨基-1-丁醇的制备方法 |
CN110683960A (zh) * | 2019-08-22 | 2020-01-14 | 台州达辰药业有限公司 | 一种(r)-3-氨基丁醇的合成方法 |
CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9421816D0 (en) | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
BR9510420A (pt) | 1994-12-22 | 2004-04-20 | Smithkline Beecham Plc | Azetidin-2-onas substituìdas para o tratamento de aterosclerose |
CH690264A5 (fr) | 1995-06-30 | 2000-06-30 | Symphar Sa | Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques. |
TR199701762T1 (xx) | 1995-07-01 | 1998-05-21 | Smithkline Beecham P.L.C. | Damar t�kanmas� tedavisi i�in azetidinon t�revleri. |
AU7216996A (en) | 1995-09-29 | 1997-04-28 | Smithkline Beecham Plc | A paf-acetylhydrolase and use in therapy |
JP2000502079A (ja) | 1995-12-08 | 2000-02-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体 |
WO1997021676A1 (en) | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Azetidinone compounds for the treatment of atherosclerosis |
TR199802160T2 (xx) | 1996-04-26 | 1999-04-21 | Smithkline Beecham Plc | Ateroskleroz tedavisi i�in azetidinon t�revleri. |
GB9608649D0 (en) | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
GB9626615D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626536D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
GB9626616D0 (en) | 1996-12-20 | 1997-02-05 | Symphar Sa | Novel compounds |
CA2309177A1 (en) | 1997-11-06 | 1999-05-20 | Stephen Allan Smith | Pyrimidinone compounds and pharmaceutical compositions containing them |
US6559155B1 (en) | 1998-08-21 | 2003-05-06 | Smithkline Beecham P.L.C. | Pyrimidinone derivatives for the treatment of atherosclerosis |
GB9910079D0 (en) | 1999-05-01 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
CN1286822C (zh) | 1999-05-01 | 2006-11-29 | 史密丝克莱恩比彻姆有限公司 | 嘧啶酮化合物 |
GB9910378D0 (en) | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
JP3757703B2 (ja) | 1999-09-22 | 2006-03-22 | 凸版印刷株式会社 | 再封可能な開口維持部材付パウチ |
JP4095804B2 (ja) | 2000-02-16 | 2008-06-04 | スミスクライン ビーチャム ピー エル シー | Ldl−pla2阻害剤としてのピリミジン−4−オン誘導体 |
GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0024807D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
GB0119793D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel compounds |
GB0119795D0 (en) | 2001-08-14 | 2001-10-03 | Smithkline Beecham Plc | Novel process |
GB0127143D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127139D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127140D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Novel compounds |
GB0127141D0 (en) | 2001-11-10 | 2002-01-02 | Smithkline Beecham Plc | Novel compounds |
GB0208279D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0208280D0 (en) * | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
CA2530816A1 (en) | 2003-07-02 | 2005-01-13 | Bayer Healthcare Ag | Amide-substituted 1,2,4-triazin-5(2h)-ones for the treatment of chronic inflammatory diseases |
DE102004061008A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one |
DE102004061009A1 (de) | 2004-12-18 | 2006-06-22 | Bayer Healthcare Ag | Substituierte 1,2,4-Triazin-5(2H)-one |
US7705005B2 (en) | 2006-10-13 | 2010-04-27 | Glaxo Group Limited | Bicyclic heteroaromatic compounds |
EP2083625A4 (en) * | 2006-10-13 | 2011-10-19 | Glaxo Group Ltd | BICYCLIC HETOROAROMATIC COMPOUNDS |
US20080090851A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080090852A1 (en) | 2006-10-13 | 2008-04-17 | Colin Andrew Leach | Bicyclic Heteroaromatic Compounds |
US20080279846A1 (en) | 2007-05-11 | 2008-11-13 | Thomas Jefferson University | Methods of treatment and prevention of neurodegenerative diseases and disorders |
EP2155225B1 (en) | 2007-05-11 | 2015-07-08 | The Trustees of the University of Pennsylvania | Methods of treatment of skin ulcers |
US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
JP2011088847A (ja) * | 2009-10-21 | 2011-05-06 | Takeda Chem Ind Ltd | 三環性化合物およびその用途 |
EP2619203A4 (en) * | 2010-09-20 | 2014-04-16 | Glaxo Group Ltd | TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF |
EP2649050A4 (en) * | 2010-12-06 | 2014-04-23 | Glaxo Group Ltd | LINKS |
US20130267544A1 (en) | 2010-12-17 | 2013-10-10 | Peter Adamson | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases |
AU2012288865B2 (en) * | 2011-07-27 | 2015-10-01 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
-
2014
- 2014-01-23 JP JP2015554039A patent/JP2016505053A/ja active Pending
- 2014-01-23 BR BR112015017397A patent/BR112015017397A2/pt not_active IP Right Cessation
- 2014-01-23 KR KR1020157022394A patent/KR20150108896A/ko not_active Application Discontinuation
- 2014-01-23 RU RU2015135824A patent/RU2015135824A/ru not_active Application Discontinuation
- 2014-01-23 EP EP14743086.2A patent/EP2948456A4/en not_active Withdrawn
- 2014-01-23 US US14/761,631 patent/US20150344485A1/en not_active Abandoned
- 2014-01-23 CA CA2899143A patent/CA2899143A1/en not_active Abandoned
- 2014-01-23 WO PCT/CN2014/071206 patent/WO2014114249A1/en active Application Filing
- 2014-01-23 AU AU2014210260A patent/AU2014210260B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
KR20150108896A (ko) | 2015-09-30 |
EP2948456A1 (en) | 2015-12-02 |
JP2016505053A (ja) | 2016-02-18 |
US20150344485A1 (en) | 2015-12-03 |
AU2014210260A1 (en) | 2015-07-30 |
EP2948456A4 (en) | 2016-09-14 |
WO2014114249A1 (en) | 2014-07-31 |
RU2015135824A (ru) | 2017-03-03 |
CA2899143A1 (en) | 2014-07-31 |
AU2014210260B2 (en) | 2016-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014001634A2 (pt) | compostos bicíclicos de pirimidona | |
EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
BR112015017397A2 (pt) | compostos pirimidona bicíclica como inibidores de lp-pla2 | |
DOP2016000195A (es) | Compuestos | |
BR112015010663A8 (pt) | formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo | |
BR112012020693A2 (pt) | derivados de ciclobutano e metilciclobutano como inibidores de janus quinase | |
BR112015028501A2 (pt) | derivados de bipirazol como inibidores de jak | |
BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
BR112015021888A8 (pt) | inibidores de dna-pk, seus usos e composição farmacêutica | |
CO7170166A2 (es) | Inhibidores de pi3k delta selectivos | |
PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
BR112014026952A8 (pt) | derivados de aminopirimidina pirazol, seus usos, e composição | |
BR112017006073A2 (pt) | derivado de ácido 4-(4-(4-fenilureído-naftalen-1-il)óxi-piridin-2-il)amino-benzoico como inibidor de quinase de p38 | |
BR112018008431A2 (pt) | composto de [1,2,4]triazolo[1,5-a]pirimidin-7-il | |
CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
BR112015021999A8 (pt) | inibidores de indoleamina 2,3-dioxigenase (ido), seus usos, composição farmacêutica, e método para inibir a atiavidade de indoleamina 2,3-dioxigenase | |
CU20130115A7 (es) | Compuestos y composiciones como inhibidores de trk | |
BR112014026703A2 (pt) | inibidores de dna-pk | |
BR112015015635A2 (pt) | inibidores de quinases de proteínas | |
UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
BR112015024671A2 (pt) | derivados de ureia úteis como inibidores de quinase | |
UY33766A (es) | COMPUESTOS CON ESTRUCTURA DE PIRIMIDINONA PARA USO EN EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR Lp-PLA2 | |
UY36224A (es) | Compuestos tricíclicos de imidazo-pirimidinona | |
BR112012022650A2 (pt) | derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2498 DE 21-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |